mesna / Generic mfg. - LARVOL DELTA

Patients with multiple sclerosis above age 60 have neurological responses to autologous hematopoietic stem cell transplants similar to younger individuals: A single center experience (ASH 2025) - "Material and methods : We analyzed MS patients who prospectively received an aHSCT following the "Mexican method." The method, previously described and registered in ClinicalTrials.govNCT02674217, employs high-dose cyclophosphamide (200 mg/Kg), rituximab 1000 mg, dexamethasone, filgrastim, and MESNA. The overall PRR of persons with MS, given aHSCT with the "Mexican method," is 75.1%, and was similar among patients aged 60 years or less. The rate of early complications of the procedure was found to be similar. Accordingly, age above 60 years should not be considered as a reason to deny aHSCT to patients with MS."

Clinical • Bone Marrow Transplantation • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Transplantation

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study (ASH 2025) - "Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, has demonstrated safety and efficacy when combined with bendamustine and rituximab in transplant-ineligible patients (pts) with relapsed DLBCL pts. We evaluated the safety and efficacy of Pola-ICE regimen—comprising polatuzumab vedotin, ifosfamide, carboplatin, and etoposide—with or without the addition of rituximab in R/R DLBCL pts in the real world...All patients received Pola-ICE: Pola 1.8 mg/kg (day 1), ifosfamide 4000 mg/m² (administered in two divided doses, days 1–2, with MESNA infusion), carboplatin AUC 4 (day 2), etoposide 100 mg/m² (days 1–3), repeated every 21 days up to 6 cycles... Pola-ICE, with or without rituximab, demonstrated promising efficacy with high-quality responses and manageable toxicity in heavily pretreated R/R DLBCL pts. This salvage regimen may serve as a viable option for high-risk patients, potentially enabling subsequent curative-intent therapies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study (ASH 2025) - "The R-MIAD regimen was planned as: rituximab 375 mg/m² d0, MTX 3.5 g/m² d1 [for those >65 years old,partially discretionary to 3g/m2 depending on the general condition of the patient], ifosfamide (IFO) 1.5g/m² d2, cytarabine (HD-AraC) 2 g/m² d3, dexamethasone (DEX) 10 mg d1-3, every 21 days as 1 cycle.Calcium folinate salvage was started every 6 h for a total of 8 doses after 24 h of MTX administrationevery 6 h for a total of 8 times, while with regular monitoring of the blood MTX concentration of MTX.During ifosfamide administration, 300 mg/m² of mesna was administered simultaneously at time 0, 4hours, and 8 hours for urinary tract protection... Our results suggest that R-MIAD regimen is a feasible, safety-manageable, and effectivecombination therapy for patients with newly diagnosed PCNSL. Prospective clinical trials are still neededfor further verification of R-MIAD regimen in first-line treatment of PCNSL."

Clinical data • Combination therapy • Observational data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Thrombocytopenia • BCL6 • IRF4 • MME

Renal and urinary adverse events following CAR-t therapy: A faers-based pharmacovigilance analysis (ASH 2025) - "This study aims to characterize the incidence and profileof RUAEs to inform safer CAR-T use in both hematologic and rheumatologic diseases.We extracted all reports in FAERS between January 2017 and March 2025 and analyzed patients whowere treated with FDA approved CAR-T products consisting of 5 anti-CD19 CAR-T products (Kymriah,Yescarta, Tecartus, Breyanz, Aucatyzl) and 2 anti-BCMA CAR-T CAR-T products (Abecma, Carvykti). We identified a comprehensive list of adverse renal and urinary reactions after CAR-T reported in FAERS.RUAEs are a clinically significant but underrecognized complication of CAR-T therapy. CD19-targetedproducts were associated with a broader range of renal toxicities than BCMA CAR-Ts. Our data confirmAKI is a common side effect of CAR-T, accounting for around 36% of reported RUAEs, but also showedadditional rare adverse events."

Adverse events • Acute Kidney Injury • Glomerulonephritis • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Rheumatology • ROR1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: St. Jude Children's Research Hospital

New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Pediatrics • Transplantation

A study on drug delivery and release kinetics of polyethylene glycol-functionalized few-layer graphene (FLG) incorporated into a gelatin-chitosan bio-composite film. (PubMed, RSC Adv) - "Uromitexan (Mesna), a cytoprotective adjuvant used during chemotherapy, was incorporated to study its drug-release behavior...Mathematical modeling revealed that the drug release kinetics mainly followed the Korsmeyer-Peppas model, driven by both Fickian diffusion (at pH 4.5 and 8.0) and non-Fickian diffusion (at pH 7.0). These findings indicate predictable drug-release behavior of the functionalized composite, suitable for infection-free applications across diverse physiological and pathological environments."

Journal • Infectious Disease

Determination of Hg(II) in water samples using silver nanoparticles functionalized with mercaptoethane sulfonate by a portable nanodrop spectrophotometry system. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "In this study, we present a spectrophotometric method for the determination of Hg2+ in water, based on its interaction with silver nanoparticles functionalized with sodium 2-mercaptoethanesulfonate (Ag@MESNA)...The proposed method is simple, rapid, and portable, enabling in-situ quantification of ionic mercury in water. Moreover, it has been successfully applied to real water samples from various sources."

Journal

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=24 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Allogeneic Bone Marrow Transplantation from HLA-Identical or Haploidentical Donors for Children and Adolescents with Sickle Cell Disease: A Feasible Curative Option (ASH 2023) - "The addition of thiotepa to the Johns Hopkins conditioning therapy backbone dor haplo BMT showed durable engraftment and excellent overall survival...5mg/kg, Busulfan (Bu, AUC 4,500), Fludarabine (Flu, 120mg/m²) or rATG, Bu, Cyclophosphamide (Cy, 200mg/kg) and with haplo donors, rATG 4...The graft-versus-host disease (GVHD) prophylaxis included Cyclosporine - Methotrexate in MSD and post-transplant Cy/mesna, mycophenolate mofetil and sirolimus in haplo... Allogeneic BMT with an HLA-identical or haploidentical family donor was feasible to treat SCD with an excellent overall survival. With a larger cohort and longer follow-up, the long-term effects of this strategy will be thoroughly studied."

Clinical • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Sickle Cell Disease • Transplant Rejection • Transplantation

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up (ASH 2024) - P1/2 | "Treatment included Bv on Days 1 and 8 at either 1.2 or 1.5 mg/kg (based on 3+3 dose-escalation schema; capped at 150 mg), ifosfamide and mesna 5 g/m2 each on Day 2, carboplatin AUC 5 (capped at 800 mg) on Day 2, and etoposide 100 mg/m2 daily on Days 1-3. Overall, five pts have died since enrollment on the study due to second cancers (3), study treatment (1), or complications of ASCT (1). Conclusions : As the field of CHL shifts to incorporate PD1-inhibitors in the front-line setting, the Bv-ICE regimen may provide primary refractory patients an effective salvage treatment option."

Clinical • Basal Cell Carcinoma • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lung Adenocarcinoma • Lung Cancer • Lymphoma • Melanoma • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • TNFRSF8

The First Case Series for Autologous Stem Cell Transplant in Multiple Sclerosis Patients in the United Arab Emirates (ASH 2024) - "This includes cyclophosphamide 50 mg/kg/iv over 2 hours daily for four days along with MESNA 50 mg/kg/day continuous infusion. A total dose of Rabbit anti-thymocyte globulin (ATG) 6.0 mg/kg/day is administered in divided doses infused over five days...All patients were treated successfully without complications with Valganciclovir. One patient had EBV reactivation only and was treated successfully with only a dose of rituximab...Although most patients developed viral reactivation, this was manageable and non-life threatening. This year we plan to expand our program and accommodate more patients from the region and beyond"

Clinical • CNS Disorders • Hematological Disorders • Multiple Sclerosis • Transplantation • CD34

Results of the Regimen Dime in Diffuse Large B-Cell Lymphoma with MYC over-Expression: A Retrospective Analysis (ASH 2024) - "Introduction : Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with a curative rate of 60% using standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)...Rituximab or obinutuzumab were administered at Day 0 of each cycle, followed by DIME (methotrexate 2 g/m2 infusion over 6 hours (day 1), dexamethasone 40 mg/day, ifosfamide 1500 mg/m2 infusion concurrent with mesna 900 mg/m2, and etoposide 100 mg/m2 infusion over 2 hours (days 2-4)).Methods : Data of patients with primary DLBCL who received R/O-DIME in the frontline setting from January 2016 up to June 30, 2023 were retrospectively reviewed...The rate of CNS disease relapse and survivals are comparable to figures quoted in literature for this subgroup of high-risk DLBCL patients treated with R-CHOP. Further studies are needed to analyze its effect on lymphomas with MYC translocation and double hit lymphomas."

IO biomarker • Retrospective data • B Cell Lymphoma • CNS Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC

Hemorrhagic Cystitis after Allogeneic or Autologous Hematopoietic Cell Transplantation in Pediatric Patients: Continuous Versus Intermittent Mesna (ASH 2024) - "Introduction Hemorrhagic cystitis (HC) is a complication of hematopoietic cell transplantation (HCT) which may result from conditioning regimens that utilize the alkylating agent cyclophosphamide. Although the primary endpoint did not reach statistical significance, this study suggests that those benefits are also likely true among a broad pediatric HCT population. There appears to be particular benefit among patients with DNA breakage disorders such as Fanconi Anemia and in patients receiving cumulative cyclophosphamide doses >100mg/kg."

Clinical • Anemia • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Transplantation

A Rare Case of High-Grade Undifferentiated Pleomorphic Sarcoma of the Terminal Ileum in a 40-Year-Old Man: Successful Outcome and Prolonged Survival After Surgical Resection and Adjuvant Chemotherapy. (PubMed, Cureus) - "The patient underwent successful surgical resection with negative margins, followed by adjuvant chemotherapy with the Adriamycin, ifosfamide, and mesna (AIM) regimen. At his 30-month follow-up, the patient remains disease-free. In conclusion, the complete surgical resection of UPS of the small intestine, combined with adjuvant chemotherapy, can lead to favorable outcomes and long-term disease-free survival."

Journal • Colorectal Cancer • Oncology • Sarcoma • Small Intestinal Carcinoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24). (PubMed, Clin Lung Cancer) - "Durvalumab combined with doxorubicin and ifosfamide suggested clinical activity in recurrent and/or metastatic PSC. Larger studies are warranted to confirm benefits and refine treatment strategies."

Journal • P2 data • Lung Cancer • Oncology • Sarcoma • Solid Tumor • PD-L1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - P1/2 | N=260 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2027 ➔ Jun 2028

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Myelodysplastic Syndrome • Transplantation • HLA-B • HLA-C • IGH

Lupus enteritis and peritonitis as a first presentation of systemic lupus erythematosus: a case report. (PubMed, BMC Rheumatol) - "Systemic lupus erythematosus (SLE) is an autoimmune illness that causes uncommon gastrointestinal symptoms such as lupus enteritis and peritonitis. This case demonstrates their simultaneous occurrence, underscoring the need to include SLE in the workup for gastrointestinal symptoms. Proper diagnosis by laboratories, imaging, and gastroscopy is critical since early intervention dramatically improves patient outcomes."

Journal • Alopecia • Cardiovascular • Endocrine Disorders • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Vasculitis

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov) - P3 | N=479 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Ependymoma • Oncology • Solid Tumor

IS-free Treg HaploHCT (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Dana-Farber Cancer Institute | N=20 ➔ 30 | Trial completion date: Dec 2030 ➔ Aug 2029 | Trial primary completion date: Dec 2029 ➔ Aug 2028

Enrollment change • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • HLA-DRB1 • TP53

Advanced Practice Provider-Led Outpatient Lymphodepleting Chemotherapy Administration for Patients Receiving Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Advanced Melanoma (JADPRO 2025) - "Introduction / Background In February 2024, lifileucel became the first FDA-approved adoptive cell therapy for the treatment of any solid tumor and was specifically approved to treat advanced melanoma. The package insert specifies a lymphodepleting (LD) chemotherapy regimen of cyclophosphamide 60 mg/kg IV with mesna for 2 days, followed by fludarabine 25 mg/m2 IV for 5 days before cell infusion...Infection prophylaxis: • Acyclovir - Start on Day -7...Olanzapine-Start on Day -8 at bedtime & continue nightly for up to one week...Ondansetron - Day -7 through Day -3 as pre-medication to chemotherapy...Prochlorperazine - Prescription provided for breakthrough nausea...It will be essential to better define the training for APPs in solid tumor cellular therapies. Continued exploration of APP-led outpatient models may reduce hospital stays, improve patient outcomes and satisfaction, and lower healthcare costs-benefiting not only melanoma patients but potentially those with..."

Clinical • Metastases • Tumor-infiltrating lymphocyte • Hematological Disorders • Infectious Disease • Melanoma • Oncology • Solid Tumor

A RARE CASE OF PLEUROPULMONARY SYNOVIAL SARCOMA PRESENTING WITH RECURRENT UNILATERAL PNEUMOTHORACES (CHEST 2025) - "She has received neoadjuvant chemoradiation with doxorubicin, ifosfamide, and mesna followed by bulk resection of the sarcoma. This case highlights a unique presentation of a rare thoracic malignancy. Owing to heterogenous clinical presentation and relative rarity, timely diagnosis of PPSS is challenging but important due to its aggressive nature. Our experience adds to a growing body of literature that details the diagnosis of PPSS after recurrent pneumothoraces, highlighting an interesting variant in the natural history of this condition."

Clinical • Cough • Infectious Disease • Lung Cancer • Oncology • Respiratory Diseases • Sarcoma • Solid Tumor • Synovial Sarcoma • Thoracic Cancer

THE ENIGMA OF RECURRENT PLEURAL AND PERICARDIAL EFFUSIONS WITH TAMPONADE: A CASE OF CARDIAC ANGIOSARCOMA (CHEST 2025) - "Subsequently, she was initiated on salvage chemotherapy (Adriamycin, Ifosfamide, Mesna). Clinical presentation of cardiac angiosarcoma is vague [2]. It is crucial to have a high index of suspicion cardiac angiosarcoma in patients presenting with recurrent and unexplained pericardial effusion. A prompt and timely diagnosis could potentially mitigate the fatal consequences of metastatic cardiac angiosarcoma."

Clinical • Angiosarcoma • Cardiovascular • Immunology • Oncology • Pulmonary Disease • Rheumatology • Sarcoma • Solid Tumor

PULMONARY ARTERY SARCOMA MIMICKING PULMONARY EMBOLISM: A DIAGNOSTIC DILEMMA HIGHLIGHTING CLINICAL GAPS AND IMAGING INSIGHTS (CHEST 2025) - "Chemotherapy with doxorubicin, ifosfamide, and mesna was initiated. PAS should be considered in patients with persistent symptoms and progressive imaging findings despite anticoagulation for PE. Red flags such as thrombectomy failure and absence of right heart strain should prompt further imaging and biopsy. A structured diagnostic approach and multidisciplinary collaboration can facilitate early diagnosis and improve outcomes in this rare malignancy."

Clinical • Cardiovascular • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Oncology • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Type 2 Diabetes Mellitus • CD31 • PECAM1

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis (clinicaltrials.gov) - P2 | N=8 | Recruiting | Sponsor: Paul Szabolcs | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial primary completion date • Cardiovascular • Hypertension • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Transplantation

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: St. Jude Children's Research Hospital | N=56 ➔ 108

Enrollment change • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • CD123 • IL3RA